HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Yumi Matsuyama Selected Research

Liposarcoma

2/2022GPR64, Screened from Ewing Sarcoma Cells, Is a Potential Target for Antibody-Based Therapy for Various Sarcomas.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Yumi Matsuyama Research Topics

Disease

2Neoplasms (Cancer)
02/2022 - 04/2021
1Sarcoma (Soft Tissue Sarcoma)
02/2022
1Ewing Sarcoma (Sarcoma, Ewing)
02/2022
1Synovial Sarcoma (Synovioma)
02/2022
1Leiomyosarcoma
02/2022
1Liposarcoma
02/2022
1Cardiomyopathies (Cardiomyopathy)
04/2008
1Hypokinesia (Bradykinesia)
04/2008

Drug/Important Bio-Agent (IBA)

1G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA
02/2022
1Pharmaceutical PreparationsIBA
02/2022
1Monoclonal AntibodiesIBA
02/2022
1Messenger RNA (mRNA)IBA
02/2022
1RNA (Ribonucleic Acid)IBA
02/2022
1fibrin fragment D (D-dimer)IBA
04/2021
1antithrombin III-protease complexIBA
04/2021
1Antifibrinolytic Agents (Antifibrinolytics)IBA
04/2021
1FibrinIBA
04/2021

Therapy/Procedure

1Therapeutics
02/2022
1Aftercare (After-Treatment)
04/2008